Shire (SHPG) has settled its litigation against Teva Pharmaceuticals USA (TEVA) in connection with Teva's abbreviated new drug application for a generic version of Shire's Intuniv Extended Release Tablets for the treatment of Attention Deficit Hyperactivity Disorder. The settlement provides Teva with a license to market in the United States either its own generic versions of Intuniv or authorized generic versions of Intuniv supplied by Shire. The license takes effect after the expiration of the 180 day exclusivity period granted to Actavis (ACT), as the first ANDA filer. Actavis is licensed by Shire to market generic product beginning on December 1, 2014.
- Health Care Industry